Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Modalities by Cytogenetic Analyses of Circulating CD34+Cells
Launched by INSTITUT FUER ANWENDUNGSORIENTIERTE FORSCHUNG UND KLINISCHE STUDIEN GMBH · May 17, 2011
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
Chromosomal aberrations in myelodysplastic syndromes (MDS) play a major role in diagnostics, pathogenesis, prognosis, and, more recently, in treatment allocations. Chromosomal anomalies can be detected by conventional chromosome banding analyses of bone marrow metaphases and most of them are provable by Fluorescence in situ hybridization (FISH) of circulating CD34+ progenitor cells from peripheral blood. For this prospective multicenter non-interventional diagnostic study sequential FISH analyses are performed on immunomagnetically enriched circulating CD34+ cells from peripheral blood as f...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis (cytomorphologic proof) of primary or secondary myelodysplastic syndrome (MDS) or
- • Suspected myelodysplastic syndrome (MDS).
- • Age \> 18 years
About Institut Fuer Anwendungsorientierte Forschung Und Klinische Studien Gmbh
Institut für Anwendungsorientierte Forschung und Klinische Studien GmbH is a leading research organization dedicated to advancing clinical research and applied science. With a strong focus on innovative methodologies and robust study designs, the institute collaborates with various stakeholders in the healthcare sector to facilitate the development and evaluation of new therapeutic interventions. By leveraging a multidisciplinary team of experts, the organization aims to enhance patient outcomes through rigorous clinical trials that adhere to the highest ethical and regulatory standards. Its commitment to excellence and scientific integrity positions it as a trusted partner in the clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Munich, , Germany
Ulm, , Germany
Dresden, , Germany
Aachen, , Germany
Düsseldorf, , Germany
Frankfurt/Main, , Germany
Frankfurt/Main, , Germany
Goettingen, , Germany
Goslar, , Germany
Göttingen, , Germany
Magdeburg, , Germany
Munich, , Germany
Northeim, , Germany
Patients applied
Trial Officials
Detlef Haase, MD, Prof.
Study Chair
University Medical Center Göttingen
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials